

## Preferred Drug List (PDL) Changes Effective January 1, 2014

On September 26, 2013, the Pharmacy and Therapeutics (P&T) Committee of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy met to review new and existing therapeutic drug classes on the Nevada Medicaid Preferred Drug List (PDL).

The actions taken by the committee are indicated below. All changes are effective January 1, 2014. The complete PDL is posted on the "<u>Preferred Drug List</u>" webpage.

Drug Class	Drugs Added as Preferred	Drugs Added as Non-Preferred
Alzheimer's Agents	Namenda® XR Tabs	None
Analgesics: Long-Acting Narcotics	Fentanyl Patch (PA required)	Kadian®
Anaphylaxis : Self-Injectable Epinephrine	Auvi-Q®	None
Anti-Migraine Agents: Triptans	Zomig®ZMT	Maxalt® Tabs*
Antiparkinson's Agents: Non-Ergot Dopamine Agonists	None	Neupro®*
Cardiovascular: Antihyperlipidemics, Statins and Statin Combinations	None	Liptruzet®
Diabetic Agents: Meglitinides and Combinations	None – List has been consolidated for consistency	None
Diabetic Agents: DPP-4 Inhibitors and Combinations	None	Jentadueto®* Kazano®* Nesina®* Oseni®* Tradjenta®*
Diabetic Agents: Other Agents	Invokana®	None
Impetigo Agents: Topical	None	Altabax®
Ophthalmic Antihistamines	None	Bepreve® Emadine® Patanol® Zaditor® OTC

Drug Class	Drugs Added as Preferred	Drugs Added as Non-Preferred
Ophthalmic Non-Steroidal Anti- Inflammatory Agents	None	Ilevro®
Pediculocides / Scabicides	Sklice®	None
Respiratory: Intranasal Rhinitis Agents	Dymista® Patanase®	Azelastine
Urinary Tract Antispasmodics	Oxybutynin ER tabs	Detrol® LA

\* Recipients with a paid claim within the last 90 days will be allowed to continue receiving this drug without a Standard Preferred Drug List Exception prior authorization.